Two Human Antibodies to a Meningococcal Serogroup B Vaccine Antigen Enhance Binding of Complement Factor H by Stabilizing the Factor H Binding Site

Overview

Journal PLoS Pathog

Specialty Microbiology

Date 2021 Jun 14

PMID 34125873

Citations 1

Authors

Nathaniel A Sands

Peter T Beernink

Affiliations

Soon will be listed here.

Abstract

Microbial pathogens bind host complement regulatory proteins to evade the immune system. The bacterial pathogen Neisseria meningitidis, or meningococcus, binds several complement regulators, including human Factor H (FH). FH binding protein (FHbp) is a component of two licensed meningococcal vaccines and in mice FHbp elicits antibodies that inhibit binding of FH to FHbp, which defeat the bacterial evasion mechanism. However, humans vaccinated with FHbp develop antibodies that enhance binding of FH to the bacteria, which could limit the effectiveness of the vaccines. In the present study, we show that two vaccine-elicited antibody fragments (Fabs) isolated from different human subjects increase binding of complement FH to meningococcal FHbp by ELISA. The two Fabs have different effects on the kinetics of FH binding to immobilized FHbp as measured by surface plasmon resonance. The 1.7- and 2.0-Å resolution X-ray crystal structures of the Fabs in complexes with FHbp illustrate that the two Fabs bind to similar epitopes on the amino-terminal domain of FHbp, adjacent to the FH binding site. Superposition models of ternary complexes of each Fab with FHbp and FH show that there is likely minimal contact between the Fabs and FH. Collectively, the structures reveal that the Fabs enhance binding of FH to FHbp by altering the conformations and mobilities of two loops adjacent to the FH binding site of FHbp. In addition, the 1.5 Å-resolution structure of one of the isolated Fabs defines the structural rearrangements associated with binding to FHbp. The FH-enhancing human Fabs, which are mirrored in the human polyclonal antibody responses, have important implications for tuning the effectiveness of FHbp-based vaccines.

Citing Articles

Extensive Genetic Diversity and Epidemiological Patterns of Factor H-Binding Protein Variants among in China.

Tan Z, Xu J, Che J, Xu L, Yan D, Zhang M Microorganisms. 2024; 12(3).

PMID: 38543533 PMC: 10972410. DOI: 10.3390/microorganisms12030481.

References

Wong E, Hallam T, Brocklebank V, Walsh P, Smith-Jackson K, Shuttleworth V . Functional Characterization of Rare Genetic Variants in the N-Terminus of Complement Factor H in aHUS, C3G, and AMD. Front Immunol. 2021; 11:602284. PMC: 7840601. DOI: 10.3389/fimmu.2020.602284. View

Veggi D, Bianchi F, Santini L, Lo Surdo P, Chesterman C, Pansegrau W . 4CMenB vaccine induces elite cross-protective human antibodies that compete with human factor H for binding to meningococcal fHbp. PLoS Pathog. 2020; 16(10):e1008882. PMC: 7556464. DOI: 10.1371/journal.ppat.1008882. View

Bianchi F, Veggi D, Santini L, Buricchi F, Bartolini E, Lo Surdo P . Cocrystal structure of meningococcal factor H binding protein variant 3 reveals a new crossprotective epitope recognized by human mAb 1E6. FASEB J. 2019; 33(11):12099-12111. PMC: 6902690. DOI: 10.1096/fj.201900374R. View

Konar M, Pajon R, Beernink P . A meningococcal vaccine antigen engineered to increase thermal stability and stabilize protective epitopes. Proc Natl Acad Sci U S A. 2015; 112(48):14823-8. PMC: 4672778. DOI: 10.1073/pnas.1507829112. View

Giuntini S, Beernink P, Granoff D . Effect of complement Factor H on anti-FHbp serum bactericidal antibody responses of infant rhesus macaques boosted with a licensed meningococcal serogroup B vaccine. Vaccine. 2015; 33(51):7168-7175. PMC: 4684420. DOI: 10.1016/j.vaccine.2015.10.135. View

Welsch J, Rossi R, Comanducci M, Granoff D . Protective activity of monoclonal antibodies to genome-derived neisserial antigen 1870, a Neisseria meningitidis candidate vaccine. J Immunol. 2004; 172(9):5606-15. DOI: 10.4049/jimmunol.172.9.5606. View

Liebschner D, Afonine P, Baker M, Bunkoczi G, Chen V, Croll T . Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix. Acta Crystallogr D Struct Biol. 2019; 75(Pt 10):861-877. PMC: 6778852. DOI: 10.1107/S2059798319011471. View

Vu D, Pajon R, Reason D, Granoff D . A broadly cross-reactive monoclonal antibody against an epitope on the n-terminus of meningococcal fHbp. Sci Rep. 2012; 2:341. PMC: 3314305. DOI: 10.1038/srep00341. View

Wallace A, Laskowski R, Thornton J . LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng. 1995; 8(2):127-34. DOI: 10.1093/protein/8.2.127. View

10.

Lewis L, Vu D, Granoff D, Ram S . Inhibition of the alternative pathway of nonhuman infant complement by porin B2 contributes to virulence of Neisseria meningitidis in the infant rat model. Infect Immun. 2014; 82(6):2574-84. PMC: 4019150. DOI: 10.1128/IAI.01517-14. View

11.

Jiang H, Hoiseth S, Harris S, McNeil L, Zhu D, Tan C . Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine. 2010; 28(37):6086-93. DOI: 10.1016/j.vaccine.2010.06.083. View

12.

Beernink P, Shaughnessy J, Braga E, Liu Q, Rice P, Ram S . A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccination. J Immunol. 2011; 186(6):3606-14. PMC: 3098282. DOI: 10.4049/jimmunol.1003470. View

13.

Schneider M, Prosser B, Caesar J, Kugelberg E, Li S, Zhang Q . Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. Nature. 2009; 458(7240):890-3. PMC: 2670278. DOI: 10.1038/nature07769. View

14.

Folaranmi T, Rubin L, Martin S, Patel M, MacNeil J . Use of Serogroup B Meningococcal Vaccines in Persons Aged ≥10 Years at Increased Risk for Serogroup B Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep. 2015; 64(22):608-12. PMC: 4584923. View

15.

Beernink P, Granoff D . The modular architecture of meningococcal factor H-binding protein. Microbiology (Reading). 2009; 155(Pt 9):2873-2883. PMC: 2859308. DOI: 10.1099/mic.0.029876-0. View

16.

Beernink P, Welsch J, Bar-Lev M, Koeberling O, Comanducci M, Granoff D . Fine antigenic specificity and cooperative bactericidal activity of monoclonal antibodies directed at the meningococcal vaccine candidate factor h-binding protein. Infect Immun. 2008; 76(9):4232-40. PMC: 2519416. DOI: 10.1128/IAI.00367-08. View

17.

Makou E, Herbert A, Barlow P . Functional anatomy of complement factor H. Biochemistry. 2013; 52(23):3949-62. DOI: 10.1021/bi4003452. View

18.

Granoff D, Giuntini S, Gowans F, Lujan E, Sharkey K, Beernink P . Enhanced protective antibody to a mutant meningococcal factor H-binding protein with low-factor H binding. JCI Insight. 2016; 1(14):e88907. PMC: 5033880. DOI: 10.1172/jci.insight.88907. View

19.

Dopler A, Guntau L, Harder M, Palmer A, Hochsmann B, Schrezenmeier H . Self versus Nonself Discrimination by the Soluble Complement Regulators Factor H and FHL-1. J Immunol. 2019; 202(7):2082-2094. DOI: 10.4049/jimmunol.1801545. View

20.

Beernink P, LoPasso C, Angiolillo A, Felici F, Granoff D . A region of the N-terminal domain of meningococcal factor H-binding protein that elicits bactericidal antibody across antigenic variant groups. Mol Immunol. 2009; 46(8-9):1647-53. PMC: 2673115. DOI: 10.1016/j.molimm.2009.02.021. View